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EPIDEMIOLOGY OF THE PROSTATE 
CANCER IN ELDERLY MEN
Prostate cancer is diagnosed (and often treated) in 
1 of 6 men, however it is the cause of death of only 3% 
of men [1]. It is the most commonly diagnosed single 
malignancy (almost 220,000 cases in 2007) in the 
United States [2]. Prostate cancer more often affects 
elderly men and thus it is a bigger health concern in de-
veloped countries. Increasing incidence rates in these 
countries are likely to be a part of the widespread and 
still increasing prostate-specific antigen testing and 
as well increased life expectancy. Prostate-specific 
antigen screening is associated with psychological 
harms, and its potential benefits remain uncertain. 
This considerable amount of prostate cancer cases 
would be much higher if it would included all the cancer 
cases in elderly men that remain undiagnosed under 
normal circumstances. According to some reports 
the chance of finding cancer within the prostate is 
29% in population of males older then forty and this 
percentage is rising among elderly. The probability of 
finding clinically significant prostate cancer obtained 
from biopsy in an autopsy study is only 43% among all 
 diagnosed prostate cancers. The results of autopsy 
and screening studies suggest that prostate cancer 
may be found even in about 80% of males over the 
age of 80, but most of those tumors are clinically 
insignificant [3–5]. It is interesting why only a small 
proportion of elderly men die of prostate cancer while 
most of them harbor lesions in their prostate glands. 
This phenomenon occurs not because of highly ef-
fective treatment as according to some studies. Such 
statistical results of prostate cancer management are 
rather because of indolent biology of most of them. The 
majority of cancers are not even diagnosed in elderly. 
These cancers that do not influence patient’s survival 
are referred to as ‘clinically irrelevant’ or ‘latent’. Ac-
cording to Parker et al. [6], there is a significant differe-
nce in disease course dependent on patient’s age at 
diagnosis — patients over 70 have much lower chance 
of dying from prostate cancer than those aged 55–60. 
The age of patient who was diagnosed cancer is too 
simple explanation of the observed phenomenon. 
This would indicate that the proportion of ‘clinically 
irrelevant’ cancers increases with age. Nevertheless, 
for most clinically relevant cancers curative treatment 
makes the difference between life and death. The 
management of prostate cancer includes surgery, 
radiation therapy, hormone therapy, chemotherapy, 
cryotherapy, radiofrequency and ultrasound therapy 
and combinations of these methods. It seems that 
such an armamentarium should lead to substantial 
improvement of treatment results. However, such a 
trend may not be observed. While prostate cancer in 
some cases follow an aggressive and fatal path, in a 
significant proportion of cases it behaves in an entirely 
different way, having no impact on patient’s survival. 
Some authors suggest that prostate cancer may be 
overdiagnosed even in 30–50% of cases, especially 
in elderly men, and that many of these patients are 
treated unnecessarily [7–9].
Why some prostate cancers are clinically sig-
nificant (i.e. life-threatening) but others are not? It 
seems that the key are proteins involved in control 
of regenerative potential and cell senescence. Cells 
from organisms with high renewable potential tissues 
are permanently withdrawing from the cell cycle in 
response to diverse stresses. This response, termed 
cellular senescence, is controlled by the tumor sup-
pressor proteins and constitutes a potent anticancer 
mechanism.  Nonetheless, senescent cells acquire 
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genotypic changes that may contribute to aging and 
certain age-related diseases, including late-life can-
cer [10]. It seems that «late-life low-grade» prostate 
cancer is a good example.
AGE INFLUENCES ON TUMOR BEHAVIOR
There exist other models of differences of biologi-
cal/clinical behavior of particular types of tumors oc-
curring in different age populations. These examples 
include soft tissue tumors, especially embryonal 
rhabdomyosarcoma, which typically occurs in first 
years of life. Use of nowadays treatment modali-
ties give over 90% survival. Whereas the same type 
of tumor occurring in adult or elderly, however as a 
rare entity, is known as a very malignant tumor with 
poor prognosis [11]. Same is true for majority of so 
called «–blastoma» tumors, e.g. medulloblastoma, 
Wilm’s tumor (nephroblastoma), acute lymphoblastic 
 lymphoma. Some authors were postulating that rather 
good prognosis of aforementioned tumors in children 
population reflects a different mechanisms of tumor 
development. As such tumors have morphology of 
embryonal (early stage of differentiation and matura-
tion) structure it was suggested that their development 
depends on misshaped local signaling responsible for 
proper cell differentiation and then maturation [12, 13].
IS THERE A LINK BETWEEN 
CARCINOGENESIS AND STEM CELL 
SENESCENCE?
Stem cells tissue renewal ability suggests that they 
are protected from ageing processes. Tissue ageing 
can be explained as a reduction of mitotic potential 
of its stem cells. Apart from exhaustion of mitotic 
potential, the ability of stem cells to differentiate into 
certain other cell types is also limited, for example 
hematopoetic stem cells lose the lymphopoetic ability 
while maintaining myelopoetic [14, 15]. And this is 
a natural pathway of cell differentiation. However, it 
should be viewed according to the phenomenon that 
bone marrow of elderly is less cellular and less effec-
tive — keep in mind increased infection susceptibility in 
elderly patients. This age related change of stem cells 
differentiation profile has numerous consequences. 
Disturbance of the balance of number and type of cells 
in tissue increases the risk of carcinogenesis. Marrow 
haematopoetic cells, and probably all stem cells, are 
sensitive to changes in their environment — cell-cell 
and cell-matrix interactions. These changes may 
potentially induce carcinogenesis by altering cell dif-
ferentiation profile and also reduce tissue regenerative 
potential by limiting multipotentiality of stem cells, even 
leading to unipotential differentiation directed into cell 
type other than one required for tissue renewal [14, 16]. 
Not only epigenetic factors, but also the ones related to 
internal information in DNA changes (for instance DNA 
methylation) influence stem cells ageing [17]. Expres-
sion of certain genes change during stem cells ageing, 
expression of the ones connected with cell metabo-
lism decreases, while expression of genes encoding 
proteins taking part in cell adhesion is increased [14]. 
Genome stability, which is closely related with genome 
repair processes, also plays an important part in stem 
cells ageing. Reduced expression of proteins taking 
part in DNA repair processes has been observed in 
ageing haematopoetic stem cells. This phenomenon 
also increases the risk of carcinogenesis and reduces 
stem cells tissue regeneration potential [14, 16, 18].
Stem cells ageing processes has an impact on cell 
division. Differentiated diploidic cells undergo sym-
metrical division resulting in two daughter cells with 
lower proliferative potential. Cells divide until they 
reach replication senescence, a state discovered in 
vitro and described by Hayflick and Moorhead [19].  It 
is difficult to clearly define the role of cells senescence 
as the genetic mechanisms involved in organisms 
ageing are still not fully explained. Hayflick [20] sug-
gests that genetic processes programmed to ensure 
proper organism development until the reproduc-
tive age are the basis of ageing. While in this part of 
organism development, biological phenomena laws 
appear to have a clear purpose, functioning of the 
organisms in the period of time between achieving 
reproductive maturity and death is more problematic. 
An important question is whether cells and organisms 
ageing is a result of the same genetic program that 
leads to  reproductive maturity, inability of repairing 
accumulated random changes leading to the loss of 
proliferative and regenerative potential or a combina-
tion of both processes [20]. In case of cells and single-
celled organisms replicative life span can be defined 
as the number of daughter cells produced by a mother 
cell before senescence [21]. There is a growing body 
of evidence that ageing processes in stem cells are 
similar to the ones in differentiated ones [22]. This phe-
nomenon is more complex because stem cells must 
perform two opposite functions: they must multiply, 
which leads to cell senility, and simultaneously they 
must maintain replicative youth. The number of cells 
with numerous replication errors, including stem cells, 
increases in tissues of ageing organisms, which inevi-
tably leads to death of cells and the entire organism 
[20, 23–25]. Cell proliferative potential depends on 
its age defined as number of divisions the cell has 
already underwent. Determination of cell age based 
on accumulated replication errors and DNA metylation 
is a reliable information about number of cell divisions 
[26, 27]. This method, however, has a limited reliability 
because of differences in stem cells division kinetic 
in tissues. It also does not allow to determine cell 
absolute age. Cell age based on number of divisions 
is different in tissues where stem cells divide continu-
ously, i.e. intestine epithelium, different in tissues with 
periodical growth (i.e. hair) in which stem cells die with 
every growth cycle and finally different in tissues with 
low mitotic rate, for example nervous tissue. Cells’ 
mitotic age may be significantly different in different 
tissues of an organism [27]. An important question is 
whether the absolute age of stem cells has a biologi-
cal significance. Stem cells ability to proliferate and 
 differentiate decreases with organism age [15]. Num-
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ber of fetal defects increases with chronological age 
of gametes indicating that chronological age of cells 
is also a significant factor. Determination of cell mitotic 
age is further complicated by the fact that in case of 
stem cells different types of cell division occurs, some 
of which were only described in theoretical models  [28, 
29]. According to the most common concept of stem 
cells division, the asymmetric division theory, when 
a stem cell divides, one of daughter cells remains in 
stem cell layer and the other one differentiates. This 
division type can be observed in epithelia and nervous 
tissue of mammals. In many tissues, however, asym-
metric divisions were not observed [29, 30]. It has not 
been proven whether asymmetric division model is an 
ideal one providing an inexhaustible pool of progenitor 
cells. Other stem cells division models perform the 
same functions and are equally probable. A stem cell 
can also undergo symmetrical division resulting in two 
daughter stem cells or two differentiating cells. In this 
case, the type of division is influenced by the stem 
cell’s environment [31–34].
Brecher et al. [35] define clonal succession, a stem 
cells division theory originally proposed by Kay [36], as 
a continuous release of stem cells for differentiation. 
Kay in his hypothesis assumes the existence of a pool 
of stem cells, some of which undergo symmetrical 
division and differentiation.
Cells’, including stem cells, ageing is connected 
with progressing deterioration of genes functions, 
which together with certain toxic factors, consecutive 
cells division and loss of DNA repair abilities lead to 
cell’s death. Epigenetic factors also have a significant 
influence on cells ageing. All these processes reduce 
cells regenerative potential and increase the risk of 
neoplastic transformation [14, 31].
DOES CELLULAR SENESCENCE EXPLAIN 
INDOLENT PROSTATE CANCERS AT 
ELDERLY?
Tissue aging is connected to exhaustion of mitotic 
potential of stem cells responsible for its renewal. 
Stem cells must take part in two seemingly opposite 
processes, in first which leads to aging and loss of 
replication potential of stem cells and in the second 
in which these cells have to preserve this potential. 
Normal, differentiated diploid cells undergo symmetric 
division resulting in two daughter cells with lower pro-
liferative potential. Cells divide until reaching ‘replica-
tion senescence’, discovered almost fifty years ago. 
Aging processes are similar in differentiated cells and 
stem cells [22]. In later, apart from reduction of mitotic 
potential, the ability to differentiate is also reduced in 
these cells [14, 15]. Normal prostate epithelial stem 
cells and prostate cancer stem cells have a similar phe-
notype. These cells have a similar expression profile 
of certain proteins, such as CD44, CD133, CXCR4 re-
ceptor and integrin α2β1. It should be emphasized, 
that immortalization of prostate epithelial cells makes 
their phenotype similar to stem cells. Normal epithelial 
prostate stem cells and prostate cancer cells have 
similar proliferative and regenerative abilities, the lat-
ter ones also have metastasize and invasive abilities 
[37]. Cancer cells are believed to originate from stem 
cells population. Cancer cells with luminal phenotype 
are unable to form tumors in animal models, which 
confirms the hypothesis of cancer stem cells role in 
tumor formation [38–40]. Stem cells are sensitive to 
changes in interaction between cells and between cell 
and extracellular matrix. These changes may, along 
with age, result in change of differentiation profile of 
stem cells, which is connected with increased risk of 
carcinogenesis, and reduced regeneration potential. 
In extreme situation it may even lead to ‘unipoten-
tiality’ with cell differentiation not directed to tissue 
renewal or generative layer atrophy [14, 15, 38]. In 
prostate cancer, atrophy of generative layer of acinar 
epithelium can be observed. P63 protein is absent in 
prostate cancer cells. Apart from epigenetic, stem 
cells aging is influenced by DNA-related phenomena, 
like genome stability [17]. An age-related decrease in 
expression of DNA-repair proteins can be observed, 
which impairs genome stability and increases the risk 
of carcinogenesis . In aging tissues, the proportion of 
cells with multiple replication errors increases, also 
among stem cells. Some of such events were attri-
buted to increasing levels of methylation. Such mo-
dels were tested in laryngeal, hematologic, and colon 
neoplasms. Number of replication errors and degree 
of DNA methylation are correlated with number of cell 
divisions and also with cell age [27]. Cells aging, reduc-
tion of regenerative potential and probability of cancer 
transformation are also influenced by epigenetic fac-
tors [14, 31]. The function of P53 protein is an example 
of mentioned adaptation to mutagenic factors. This 
protein is inactive in young cells, which allows them to 
maintain high regenerative potential. Young cells have 
a low number of accumulated mutations and thus low 
P53 activity in these cells does not result in increased 
risk of carcinogenesis. In older cells, when DNA repair 
is necessary, increased P53 activity is an important 
factor limiting cell divisions. This allows cells to repair 
replication errors and decreases tissue regenerative 
potential — cells proliferate slower but maintain ge-
nome stability. As a result of cell aging, P53 protein 
may undergo mutation and lose the ability to regulate 
cell cycle. However, in colon cancer model P53 ex-
pression was found to be increased, but it is inactive 
form of mutated protein. In such circumstances cells 
regain the ability to proliferate but, because of accu-
mulation of mutation and other changes in genome, 
their ability to regenerate proper/normal tissue is 
diminished. Such cells often undergo cancer transfor-
mation as a result of numerous accumulated mutations 
[16, 41–44]. Mechanisms that regulate regenerative 
potential and prevent carcinogenesis are similar. 
Cell aging in stem cells disturb the balance between 
the ability to regenerate and processes preventing 
 oncogenesis. Carcinogenesis in an elderly is a process 
connected with decreased regenerative potential of 
tissues. Prostate cancer, with basal layer atrophy 
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(no P63 protein expression) and acinar neoplasia are 
examples of such processes. Prostate cancer in an 
elderly is probably a consequence of both, cellular 
senescence and diminished regenerative potential.
CONCLUSIONS
Prostate cancer could be divided into two distinct 
clinical phenotypes with similar pathological features. 
One type is an aggressive prostate cancer, which is a 
life-threatening disease usually diagnosed in relatively 
young men between 55–65 years old [45]. The  se cond 
one is a clinical insignificant cancer, which does not 
affect life expectancy. Most of these cancers are 
 diagnosed in men around 75–80 years old. These men 
have usually elevated prostate specific antigen (PSA). 
The most difficult task is the identification and early 
radical treatment of all clinically significant cancers 
and possibly the lowest rate of positive «false» diag-
noses of insignificant cancers [46]. There is no need 
to treat patients with insignificant cancers, because 
no profit from this management will be expected. The 
next problem is cost-effectiveness in global (popula-
tion) based studies.
The main problem is that many patients with late-
life low-grade prostate cancers are offered an arma-
mentarium of treatment methods. The treatment of 
prostate cancer is often connected with many side 
effects related to extensive surgical procedures, 
hormonal manipulations and radiation therapies. All 
these treatment methods have a negative effect on 
the quality of life of elderly people.
Based on clinical data and experimental work a 
subtype of late-life low-grade prostate cancer sub-
category should be established. This «cancer» should 
rather be viewed as a senescence-related feature and 
probably not treated at all.
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